Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc. (OLMA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
olma · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Olema Pharmaceuticals, Inc. (OLMA) measures how much investors pay for each dollar of the company's trailing earnings. OLMA's current PE ratio of N/A is calculated by dividing its stock price of $10.07 by its TTM earnings per share of -$1.80.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2018 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Olema Pharmaceuticals, Inc.You OLMA | $880M | N/A | — | -$1.80 |
 Absci Corporation ABSI | $1.0B | N/A | — | -$0.84 |
 Corvus Pharmaceuticals, Inc. CRVS | $940M | N/A | — | -$0.19 |
 4D Molecular Therapeutics, Inc. FDMT | $450M | N/A | — | -$2.42 |
 Gossamer Bio, Inc. GOSS | $39M | N/A | — | -$0.75 |
 KalVista Pharmaceuticals, Inc. KALV | $1.4B | N/A | — | -$3.23 |
 Lexicon Pharmaceuticals, Inc. LXRX | $846M | N/A | — | -$0.14 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.87 | — | |
2024-12-31 FY2024 | — | $-2.20 | — | |
2023-12-31 FY2023 | — | $-2.14 | — | |
2022-12-31 FY2022 | — | $-2.62 | — | |
2021-12-31 FY2021 | — | $-1.80 | — | |
2020-12-31 FY2020 | — | $-0.56 | — | |
2019-12-31 FY2019 | — | $-0.11 | — | |
2018-12-31 FY2018 | — | $-0.16 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Olema Pharmaceuticals, Inc. (OLMA) measures how much investors pay for each dollar of the company's trailing earnings. OLMA's current PE ratio of N/A is calculated by dividing its stock price of $10.07 by its TTM earnings per share of -$1.80.
Frequently asked questions
OLMA pe ratio · 6 questionsOLMA's current PE ratio is N/A as of 2026-06-08, based on a stock price of $10.07 and TTM EPS of -$1.80. Data sourced from Financial Modeling Prep via OLMA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Olema Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08